Diabetes Medicines
Methodology & AI Transparency ⓘ
Diabetes Medicines Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is diabetes? Diabetes is a disease in which your blood glucose, or blood sugar , levels are too high.
- 2 Real-world patient consensus: Diagnostic registry E09.7: Diabetes Medicines is managed within Diabetes & Glucose.
- 3 Typical cash cost range: Clinicians assessing Diabetes Medicines focus on impaired incretin GLP-1/GIP in Diabetes Medicines (E09.7: signaling) and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Diabetes Medicines: Fasting Plasma Glucose [Diabetes Medicines E09.7] (75 – 95 mg/dL (E09.7)) and Fasting Insulin [Diabetes Medicines E09.7].
Ask our AI Specialists anything about Diabetes Medicines
What Is Diabetes Medicines?
What is diabetes? Diabetes is a disease in which your blood glucose, or blood sugar , levels are too high. Glucose comes from the foods you eat. The cells of your body need glucose for energy. A hormone called insulin helps the glucose get into your cells. With type 1 diabetes , your body does not make insulin. With type 2 diabetes ,your body does not make or use insulin well. Without enough insulin, glucose can't get into your cells as quickly as usual. The glucose builds up in your blood and causes high blood sugar levels. What are the treatments for diabetes? Treatments for diabetes can depend on the type.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Diabetes Medicines (ICD-10 E09.7) is driven by impaired incretin GLP-1/GIP in Diabetes Medicines (E09.7: signaling); Cross-referenced with NIH MeSH (Insulins, Hypoglycemic Agents), specialists in Type 1 & Type 2 Diabetes monitor Fasting Insulin [Diabetes Medicines E09.7] to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • What your target blood sugar level is
- • What to do if your blood sugar gets too low or too high
- • Presentation of Diabetes Medicines (E09.7): elevated fasting blood in Diabetes Medicines (E09.7: glucose or post-meal)
- • Secondary Diabetes Medicines clinical sign: increased thirst [Diabetes Medicines E09.7]
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Diabetes Medicines Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E09.7 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Type 1 & Type 2 Diabetes | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Fasting Plasma Glucose [Diabetes Medicines E09.7] | 75 – 95 mg/dL (E09.7) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Insulin [Diabetes Medicines E09.7] | 3.0 – 7.0 uIU/mL (E09.7) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: CGM Time-in-Range (70–140 in Diabetes Medicines (E09.7: mg/dL)) | > 85% (E09.7) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Diabetes Medicines
Treatment selection for Diabetes Medicines depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Diabetes Medicines)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of empagliflozin as add-on to metformin for type 2: What a 4,256-Participant Study Found EMPA as add-on to MET was well tolerated and provided additional benefits beyond glucose lowering, such as weight loss and blood pressure reduction. European journal of clinical pharmacology • 2016-06-15 • Meta-Analysis | N = 4,256 | 99/100 | PMID 26832915 ↗ |
| New Insights on Is metformin still the most efficacious first-line oral hypoglycaemic drug in: What a 33,830-Participant Study Found This meta-analysis showed that repaglinide and metformin would be the most efficacious oral drugs for first-line single-drug treatment of T2DM. Obesity reviews : an official journal of the International Association for the Study of Obesity • 2019-01-15 • Meta-Analysis | N = 33,830 | 99/100 | PMID 30230172 ↗ |
| New Insights on Heart and blood vessel outcomes of liraglutide in patients with type 2: What a 14,608-Participant Study Found Our results suggest that liraglutide treatment decreases the risk of MACE, AMI, all-cause death and heart and blood vessel death among patients with type 2 diabetes. Medicine • 2019-11-15 • Meta-Analysis | N = 14,608 | 99/100 | PMID 31725627 ↗ |
| New Insights on Urinary tract infections in patients with diabetes treated with: What a 3,152-Participant Study Found Treatment of type 2 diabetes with once-daily dapagliflozin 5 or 10mg is accompanied by a slightly increased risk of urinary tract infection. Journal of diabetes and its complications • 2013-01-15 • Meta-Analysis | N = 3,152 | 99/100 | PMID 23849632 ↗ |
| New Insights on Effect of metformin on microvascular outcomes in patients with type 2: What a 18,181-Participant Study Found There is no evidence of clinically significant beneficial effect of metformin therapy as compared to other glucose-lowering medications or placebo on the examined microvascular complications. Diabetes research and clinical practice • 2022-04-15 • Meta-Analysis | N = 18,181 | 99/100 | PMID 35247521 ↗ |
Diabetes Medicines Patient Community & “People Like Me” Threads
Filter Diabetes Medicines community threads and patient logs by age, biological sex, dosage, and treatment duration.